Limits...
Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH

Related in: MedlinePlus

QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376290&req=5

fig4: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).

Mentions: The multiple linear regression models and parameter values used to generate LSMs for each of the analyses in this report are presented in Table 5Table 5QoL change score multiple linear regression parameter estimates. Table 6Table 6Regression analyses: least squares means, last assessment change scores presents LSM estimates for the seven primary QoL endpoints for the overall analysis and by disease progression status. Results of both the univariate and multiple linear regression analyses of QoL change scores for the two treatment groups are displayed in Figures 4Figure 4


Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376290&req=5

fig4: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
Mentions: The multiple linear regression models and parameter values used to generate LSMs for each of the analyses in this report are presented in Table 5Table 5QoL change score multiple linear regression parameter estimates. Table 6Table 6Regression analyses: least squares means, last assessment change scores presents LSM estimates for the seven primary QoL endpoints for the overall analysis and by disease progression status. Results of both the univariate and multiple linear regression analyses of QoL change scores for the two treatment groups are displayed in Figures 4Figure 4

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH
Related in: MedlinePlus